Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bafna Pharmaceuticals, an India-based pharmaceutical company, has received UK MHRA approval for the manufacturing of the drug Finasteride to treat enlarged prostate gland.
Subscribe to our email newsletter
The UK regulatory agency has approved Bafna for the manufacturing of Finasteride in strength of 5 mg.
Finasteride is an antiandrogen which acts by inhibiting 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It works by blocking the body’s production of the male hormone that causes the prostate to enlarge.
Bafna Pharmaceuticals CMD Mahaveer Chand Bafna said that Bafna Pharma has been constantly upgrading its manufacturing facilities to efficiently meet the anticipated demands of the global markets.
"The approval from UK MHRA for Finasteride 5 mg will enable Bafna Pharma to widen the customer base in Europe," Chand Bafna said.